Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov;12(11):651-661.
doi: 10.1038/nrneurol.2016.140. Epub 2016 Sep 23.

Pathophysiological and diagnostic implications of cortical dysfunction in ALS

Affiliations
Review

Pathophysiological and diagnostic implications of cortical dysfunction in ALS

Nimeshan Geevasinga et al. Nat Rev Neurol. 2016 Nov.

Abstract

Cortical dysfunction - specifically, the development of hyperexcitability - seems to be an early and intrinsic feature of sporadic and familial amyotrophic lateral sclerosis (ALS) phenotypes, preceding the onset of lower motor neuron dysfunction and correlating with ensuing lower motor neuron dysfunction and degeneration. In fact, cortical dysfunction could provide a pathogenic basis for ALS, with corticomotor neuronal hyperexcitability mediating motor neuron degeneration via a trans-synaptic, glutamate-mediated, excitotoxic mechanism. The recent identification of C9orf72 repeat expansion as an important genetic risk factor for both ALS and frontotemporal dementia has underscored the importance of cortical function in ALS pathogenesis, and has helped to confirm that the disease forms part of a spectrum of central neurodegenerative processes. Changes in cortical function that develop in ALS could prove useful as diagnostic biomarkers, potentially enhancing the diagnosis of ALS at an early stage of the disease process. Pathophysiological and diagnostic biomarkers of cortical function might also provide insights to guide the development of future therapeutic approaches, including stem cell and genetic interventions, thereby providing potential for more-effective management of patients with ALS.

PubMed Disclaimer

References

    1. Lancet Neurol. 2007 Oct;6(10):869-77 - PubMed
    1. Elife. 2014 Oct 14;3:null - PubMed
    1. Nat Neurosci. 1999 May;2(5):427-33 - PubMed
    1. Lancet Neurol. 2015 Aug;14(8):786-8 - PubMed
    1. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):97-100 - PubMed

MeSH terms

Substances

LinkOut - more resources